Search Results for "inflammatory-bowel-disease"
- Parlett LE , Ball K , Pipkin CA , Kappelman MD , Bocage C , Long MD . Compared to thiopurines and tumor necrosis factor inhibitors novel biologics are associated with reduced risk of non-melanoma skin cancer among patients with inflammatory bowel disease . Poster presented at 2024 International Society for Pharmacoepidemiology Annual Meeting; August 24 - August 28, 2024; .
- Lewis JD , Brensinger CM , Parlett LE , Hurtado-Lorenzo A , Kappelman MD . Provider specialization in inflammatory bowel diseases: quality of care and outcomes .Clin Gastroenterol Hepatol. 2024; 22 (12) : 2475-86.e14 . doi: 10.1016/j.cgh.2024.05.024 .
- Long MD , Parlett LE , Lewis JD et al . Corticosteroids but not anti-tnf are associated with increased covid-19 complications in patients with inflammatory bowel disease .Inflamm Bowel Dis. 2024; 30 (8) : 1345–52 . doi: 10.1093/ibd/izad176 .
- Adimadhyam S , Lewis JD , Simon AL et al . Real-world evidence comparing tofacitinib and vedolizumab in anti-tnf-experienced patients with ulcerative colitis .Inflamm Bowel Dis. 2024; 30 (4) : 554-62 . doi: 10.1093/ibd/izad115 .
- Dawwas GK , Weiss A , Constant BD et al . Development and validation of claims-based definitions to identify incident and prevalent inflammatory bowel disease in administrative healthcare databases .Inflamm Bowel Dis. 2023; 29 (12) : 1993-6 . doi: 10.1093/ibd/izad053 .
- Lewis JD , Parlett LE , Jonsson Funk ML et al . Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the united states .Gastroenterology. 2023; 165 (5) : 1197-1205.e2 . doi: 10.1053/j.gastro.2023.07.003 .
- Kappelman MD , Lewis JD , Zhang X et al . Comparing patient-reported outcomes among anti-tnf-experienced patients with crohn's disease initiating vedolizumab versus ustekinumab .Dig Dis Sci. 2023; 68 (8) : 3413-20 . doi: 10.1007/s10620-023-07942-0 .
- Kappelman MD , Long MD , Zhang X et al . Comparing patient-reported outcomes among anti-tnf experienced patients with ulcerative colitis initiating vedolizumab versus tofacitinib .Crohns Colitis 360. 2023; 5 (3) : otad031 . doi: 10.1093/crocol/otad031 .
- Kappelman MD , Adimadhyam S , Hou L et al . Real-world evidence comparing vedolizumab and ustekinumab in antitumor necrosis factor-experienced patients with crohn's disease .Am J Gastroenterol. 2023; 118 (4) : 674-84 . doi: 10.14309/ajg.0000000000002068 .